BrainStorm Cell Therapeutics Inc. reported its financial results for the first quarter ended March 31, 2025. The company, focused on developing adult stem cell therapeutics for neurodegenerative diseases, recorded a net loss of approximately $2.9 million for the quarter, a decrease from the net loss of approximately $3.4 million in the same period the previous year. Research and development expenditures increased to $1.3 million, compared to $1.0 million for the quarter ended March 31, 2024. General and administrative expenses also rose to approximately $1.8 million from approximately $1.5 million in the corresponding quarter of the prior year. In addition to financial results, BrainStorm provided a corporate update on its NurOwn® development program. The company announced an IND amendment submission for NurOwn to the U.S. Food and Drug Administration, paving the way for the initiation of a Phase 3b clinical trial. This trial, designed in collaboration with the FDA under a Special Protocol Assessment, aims to confirm the product's efficacy in early-stage ALS patients. Furthermore, BrainStorm's leadership presented biomarker insights at the 2025 ALS Drug Development Summit, emphasizing the relationship between cerebrospinal fluid biomarker pathways and clinical outcomes in ALS treatment.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。